ClinicalTrials.gg
CompletedNCT00413283Updated Oct 24, 2013Results posted

Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)

A Phase 2 interventional study of Romiplostim and Placebo in Lung Cancer, Chemotherapy-Induced Thrombocytopenia and Non-Small Cell Lung Cancer, sponsored by Amgen. Completed at 113 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-10-24.

Primary conditionCarcinoma, Non-Small-Cell LungRegistry: Lung NeoplasmsReclassifiedWhy we changed it
Registry
Lung Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Non-Small-Cell Lung
Why
  1. The study's listed conditions name Carcinoma, Non-Small-Cell Lung, a narrower term within Lung Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Amgen · Phase 2, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Carcinoma, Non-Small-Cell Lung by Amgen — 2 open to participants now, 7 under way, 4 of them phase 3. Carcinoma, Non-Small-Cell Lung · Amgen.

Enrollment
19th of 31
63 · median 145
Started
2006
with 3 others
Phase 2
14 of 40
none open now
Registered
12th of 40
by date

Among the 40 studies in Carcinoma, Non-Small-Cell Lung by Amgen, this one is the 19th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2006, is one of 14 in phase 2, and was the 12th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

2 of the 40 studies in Carcinoma, Non-Small-Cell Lung by Amgen are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Carcinoma, Non-Small-Cell Lung by Amgen, or all of them as a file.
02

Study summary

The purpose of this study is to identify an effective, well tolerated dose and schedule of romiplostim that is appropriate for the treatment of chemotherapy induced thrombocytopenia (CIT) in patients with non-small cell lung cancer receiving gemcitabine and platinum.

03

Conditions studied

  • Lung Cancer
  • Chemotherapy-Induced Thrombocytopenia
  • Non-Small Cell Lung Cancer
  • Cancer
  • Lung Neoplasms
  • Oncology
  • Solid Tumors
  • Thrombocytopenia

Keywords

  • Advanced Non-Small Cell Lung Cancer
  • Chemotherapy Induced Thrombocytopenia
  • CIT
  • NSCLC
  • Stage IIIB NSCLC
  • Stage IV NSCLC
  • Gemcitabine
  • Carboplatin
  • Cisplatin
04

In context

Carcinoma, Non-Small-Cell Lung Reclassified

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

This study's enrollment of 63 is close to the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.

Browse Carcinoma, Non-Small-Cell Lung studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Compared within Carcinoma, Non-Small-Cell Lung, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed locally advanced or stage IIIB or stage IV NSCLC receiving 21-day cycles of gemcitabine/carboplatin or gemcitabine/cisplatin
  • ≥ 12 weeks at the time of screening
  • Thrombocytopenia as evidenced by a count ≤ 50 x 10\^9/L during the qualifying cycle of chemotherapy, OR platelet count \< 100 x 10\^9/L on Day 22 of the qualifying cycle (for eligibility inclusion: ability to receive the same dose of chemotherapy on study), this criteria ensures that the patient must be dose delayed for platelet recovery
  • Ability to receive the same dose and schedule of chemotherapy during the first on-study treatment cycle as was given in the qualifying cycle (except Day 8 gemcitabine)
  • (ANC) ≥ 1,000/µL, ≥ 9.5 g/dL, and platelet count ≥ 100 x 10 \^9/L on Day 1 of the first on study chemotherapy treatment cycle
  • (ECOG) performance status of 0 to 2 at the time of screening
  • Adequate Liver function; (AST) and alanine aminotransferase (ALT) \< 3.0 x (ULN) (except for patients with a confirmed diagnosis of Gilbert's Syndrome)
  • Adequate renal function; serum creatinine \< 1.5 x ULN

Exclusion criteria

Exclusion Criteria:

  • Receipt of > 1 prior systemic chemotherapy regimen
  • Sepsis, disseminated coagulation or any other condition (i.e. immune [idiopathic] thrombocytopenic purpura [ITP], thrombotic thrombocytopenic purpura [TTP], hemolytic uremic syndrome [HUS]) that may exacerbate thrombocytopenia
  • History of unstable angina, congestive heart failure, uncontrolled hypertension (diastolic > 100 mmHg), uncontrolled cardiac arrhythmia, or recent (within 1 year of screening ) myocardial infarction
  • History of arterial thrombosis (e.g., stroke or ) within 1 year of screening
  • History of pulmonary embolism or other venous thrombosis within 1 year of screening (except for catheter-related clots)
  • Use of any nitrosourea or mitomycin-C within 6 weeks of screening
  • Have received any thrombopoietic growth factor or related substance
  • Have received granulocyte macrophage colony stimulating factor (GM-CSF) within the last 4 weeks prior to screening
  • Have received any experimental therapy within 4 weeks prior to screening
  • Have ever received a bone marrow or peripheral blood stem cell infusion (within 1 year of screening)
  • Known to any recombinant E. coli-derived product.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
63 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received a placebo subcutaneous injection on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.

    Drug: Placebo · Drug: Gemcitabine · Drug: Carboplatin · Drug: Cisplatin

  • Experimental
    Romiplostim 250 μg

    Participants received romiplostim 250 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.

    Biological: Romiplostim · Drug: Gemcitabine · Drug: Carboplatin · Drug: Cisplatin

  • Experimental
    Romiplostim 500 μg

    Participants received romiplostim 500 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.

    Biological: Romiplostim · Drug: Gemcitabine · Drug: Carboplatin · Drug: Cisplatin

  • Experimental
    Romiplostim 750 μg

    Participants received romiplostim 750 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.

    Biological: Romiplostim · Drug: Gemcitabine · Drug: Carboplatin · Drug: Cisplatin

Interventions

  • BiologicalRomiplostim

    Romiplostim is a thrombopoiesis recombinant protein that targets the thrombopoietin (TPO) receptor which results in increased platelet production.

    Also known as: AMG 531, Nplate®

  • DrugPlacebo

    Placebo subcutaneous injection.

  • Intravenous infusion

  • Intravenous infusion

  • Intravenous infusion

07

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    This summary includes all treatment-emergent adverse events recorded from the start of investigational product on this study, or any worsening of adverse events initially experienced before initiation of this study.

    Time frame: 4 months

Secondary outcomes

  1. Duration of Grade 3 or 4 Thrombocytopenia

    The duration of grade 3 or 4 thrombocytopenia (defined as platelet count \<50 x 10\^9/L) experienced during the first on study chemotherapy cycle by treatment group.

    Time frame: 3 weeks

  2. Number of Participants Experiencing Grade 3 or 4 Thrombocytopenia During the First Treatment Cycle.

    The number of participants in each treatment group with grade 3 or 4 thrombocytopenia during the first on study treatment cycle. Per the Common Terminology Criteria for Adverse Events (CTCAE) v3.0, participants with a platelet count \< 50 x 10\^9/L, but ≥ 25 x 10\^9/L are considered to have Grade 3 thrombocytopenia and participants with a platelet count \< 25 x 10\^9/L are considered to have Grade 4 thrombocytopenia. Additionally, participants with a platelet transfusion during the first on-study treatment cycle were classified as having Grade 3/4 thrombocytopenia.

    Time frame: 3 weeks

  3. Number of Participants With Platelet Transfusions

    Number of participants who were administered platelet transfusions during first on study treatment cycle.

    Time frame: 3 weeks

  4. Platelet Count on Day 22

    Platelet count on Day 22 of the first on study chemotherapy treatment cycle (planned Day 1 of next cycle) by treatment group

    Time frame: Day 22

  5. Gemcitabine Dose Reduction on Day 8 of the First Chemotherapy Cycle

    Number of participants who required a gemcitabine dose reduction on Day 8 of the first on study chemotherapy cycle.

    Time frame: 8 days

08

Results

Posted Oct 21, 2010

Participant flow

Participants were enrolled from 28 December 2006 through 11 August 2008.

Participant flow — Overall Study
MilestonePlaceboRomiplostim 250 µgRomiplostim 500 µgRomiplostim 750 µg
Started12161817
Received study drug12161816
Completed11131613
Not completed1324
Withdrew: Withdrawal by subject1001
Withdrew: Death0011
Withdrew: Adverse event0001
Withdrew: Ineligibility determined0001
Withdrew: Protocol deviation0100
Withdrew: Requirement for alternative therapy0200
Withdrew: Other0010

Outcome measures

PrimaryNumber of Participants With Adverse Events

This summary includes all treatment-emergent adverse events recorded from the start of investigational product on this study, or any worsening of adverse events initially experienced before initiation of this study.

Time frame:
4 months
Reported as:
Number · Participants
Number of Participants With Adverse Events
ParticipantsPlaceboRomiplostim 250 µgRomiplostim 500 µgRomiplostim 750 µg
Number of Participants With Adverse Events12161814
SecondaryDuration of Grade 3 or 4 Thrombocytopenia

The duration of grade 3 or 4 thrombocytopenia (defined as platelet count \<50 x 10\^9/L) experienced during the first on study chemotherapy cycle by treatment group.

Time frame:
3 weeks
Reported as:
Mean · days
Duration of Grade 3 or 4 Thrombocytopenia
daysPlaceboRomiplostim 250 µgRomiplostim 500 µgRomiplostim 750 µg
Duration of Grade 3 or 4 Thrombocytopenia2.1 ± 3.33.6 ± 4.32.6 ± 3.92.1 ± 2.7
Statistical analysis
  • Placebo vs Romiplostim 750 µg · Satterthwaite t-test · p = 0.972
  • Placebo vs Romiplostim 500 µg · Satterthwaite t-test · p = 0.725
  • Placebo vs Romiplostim 250 µg · Satterthwaite t-test · p = 0.312
SecondaryNumber of Participants Experiencing Grade 3 or 4 Thrombocytopenia During the First Treatment Cycle.

The number of participants in each treatment group with grade 3 or 4 thrombocytopenia during the first on study treatment cycle. Per the Common Terminology Criteria for Adverse Events (CTCAE) v3.0, participants with a platelet count \< 50 x 10\^9/L, but ≥ 25 x 10\^9/L are considered to have Grade 3 thrombocytopenia and participants with a platelet count \< 25 x 10\^9/L are considered to have Grade 4 thrombocytopenia. Additionally, participants with a platelet transfusion during the first on-study treatment cycle were classified as having Grade 3/4 thrombocytopenia.

Time frame:
3 weeks
Reported as:
Number · Participants
Number of Participants Experiencing Grade 3 or 4 Thrombocytopenia During the First Treatment Cycle.
ParticipantsPlaceboRomiplostim 250 µgRomiplostim 500 µgRomiplostim 750 µg
Number of Participants Experiencing Grade 3 or 4 Thrombocytopenia During the First Treatment Cycle.5777
Statistical analysis
  • Placebo vs Romiplostim 750 µg · Fisher Exact · p = 1.000
  • Placebo vs Romiplostim 500 µg · Fisher Exact · p = 1.000
  • Placebo vs Romiplostim 250 µg · Fisher Exact · p = 1.000
SecondaryNumber of Participants With Platelet Transfusions

Number of participants who were administered platelet transfusions during first on study treatment cycle.

Time frame:
3 weeks
Reported as:
Number · Participants
Number of Participants With Platelet Transfusions
ParticipantsPlaceboRomiplostim 250 µgRomiplostim 500 µgRomiplostim 750 µg
Number of Participants With Platelet Transfusions1411
Statistical analysis
  • Placebo vs Romiplostim 750 µg · Fisher Exact · p = 1.000
  • Placebo vs Romiplostim 500 µg · Fisher Exact · p = 1.000
  • Placebo vs Romiplostim 250 µg · Fisher Exact · p = 0.342
SecondaryPlatelet Count on Day 22

Platelet count on Day 22 of the first on study chemotherapy treatment cycle (planned Day 1 of next cycle) by treatment group

Time frame:
Day 22
Reported as:
Mean · 10^9/L
Platelet Count on Day 22
10^9/LPlaceboRomiplostim 250 µgRomiplostim 500 µgRomiplostim 750 µg
Platelet Count on Day 22281.2 ± 116.0222.6 ± 112.0412.8 ± 295.2336.0 ± 254.9
Statistical analysis
  • Placebo vs Romiplostim 750 µg · Satterthwaite t-test · p = 0.454
  • Placebo vs Romiplostim 500 µg · Satterthwaite t-test · p = 0.101
  • Placebo vs Romiplostim 250 µg · Satterthwaite t-test · p = 0.199
SecondaryGemcitabine Dose Reduction on Day 8 of the First Chemotherapy Cycle

Number of participants who required a gemcitabine dose reduction on Day 8 of the first on study chemotherapy cycle.

Time frame:
8 days
Reported as:
Number · Participants
Gemcitabine Dose Reduction on Day 8 of the First Chemotherapy Cycle
ParticipantsPlaceboRomiplostim 250 µgRomiplostim 500 µgRomiplostim 750 µg
Gemcitabine Dose Reduction on Day 8 of the First Chemotherapy Cycle2445
Statistical analysis
  • Placebo vs Romiplostim 750 µg · Fisher Exact · p = 0.662
  • Placebo vs Romiplostim 500 µg · Fisher Exact · p = 1.000
  • Placebo vs Romiplostim 250 µg · Fisher Exact · p = 0.662

Adverse events

Collected over From signing of the informed consent through 30 days after the last dose of investigational product or end of study, whichever is longer (up to 4 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1/12 (8.3%)12/12 (100%)
Romiplostim 250 µg—7/16 (43.8%)16/16 (100%)
Romiplostim 500 µg—5/18 (27.8%)17/18 (94.4%)
Romiplostim 750 µg—5/16 (31.3%)14/16 (87.5%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventPlaceboRomiplostim 250 µgRomiplostim 500 µgRomiplostim 750 µg
ThrombocytopeniaBlood and lymphatic system disorders1/124/160/181/16
AnaemiaBlood and lymphatic system disorders0/123/161/181/16
DyspnoeaRespiratory, thoracic and mediastinal disorders0/121/162/181/16
NeutropeniaBlood and lymphatic system disorders0/121/160/180/16
Cardiac failureCardiac disorders0/120/160/181/16
CyanosisCardiac disorders0/120/160/181/16
Abdominal painGastrointestinal disorders0/120/160/181/16
VomitingGastrointestinal disorders0/120/160/181/16
PyrexiaGeneral disorders0/120/160/181/16
Catheter related infectionInfections and infestations0/121/160/181/16
Most frequent other events
Showing 10 of 136
Most frequent other events
EventPlaceboRomiplostim 250 µgRomiplostim 500 µgRomiplostim 750 µg
AnaemiaBlood and lymphatic system disorders6/127/167/185/16
ThrombocytopeniaBlood and lymphatic system disorders4/128/168/188/16
LeukopeniaBlood and lymphatic system disorders4/124/164/182/16
NeutropeniaBlood and lymphatic system disorders2/123/163/185/16
FatigueGeneral disorders1/125/164/181/16
PyrexiaGeneral disorders0/125/162/180/16
NauseaGastrointestinal disorders1/124/165/182/16
VomitingGastrointestinal disorders3/124/161/181/16
DizzinessNervous system disorders0/124/161/181/16
CoughRespiratory, thoracic and mediastinal disorders1/121/162/184/16

Baseline characteristics

Age Continuous
Age Continuous(Years)PlaceboRomiplostim 250 µgRomiplostim 500 µgRomiplostim 750 µgTotal
Mean59.8 ± 6.663.8 ± 10.862.5 ± 7.765.4 ± 8.263.1 ± 8.5
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRomiplostim 250 µgRomiplostim 500 µgRomiplostim 750 µgTotal
Female646218
Male612121545
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboRomiplostim 250 µgRomiplostim 500 µgRomiplostim 750 µgTotal
White or Caucasian1215181762
Black or African American01001
09

Study locations

113 sites
  • Research Site
    Glendale, Arizona 85304, United States
  • Research Site
    Glendale, Arizona, United States
  • Research Site
    Anaheim, California 92801, United States
  • Research Site
    Anaheim, California, United States
  • Research Site
    Los Angeles, California 90048, United States
  • Research Site
    Los Angeles, California, United States
  • Research Site
    Rancho Mirage, California 92270, United States
  • Research Site
    Rancho Mirage, California, United States
  • Research Site
    Boynton Beach, Florida 33435, United States
  • Research Site
    Boynton Beach, Florida, United States
  • Research Site
    Vero Beach, Florida 32960, United States
  • Research Site
    Vero Beach, Florida, United States
  • Research Site
    Athens, Georgia 30607, United States
  • Research Site
    Athens, Georgia, United States
  • Research Site
    Macon, Georgia 31201, United States
  • Research Site
    Macon, Georgia, United States
  • Research Site
    Peoria, Illinois 61615, United States
  • Research Site
    Peoria, Illinois, United States
  • Research Site
    Sioux City, Iowa 51101, United States
  • Research Site
    Sioux City, Iowa, United States
  • Research Site
    Paducah, Kentucky 42003, United States
  • Research Site
    Paducah, Kentucky, United States
  • Research Site
    Shreveport, Louisiana 71101, United States
  • Research Site
    Shreveport, Louisiana, United States
  • Research Site
    Baltimore, Maryland 21201, United States
  • Research Site
    Baltimore, Maryland, United States
  • Research Site
    Sterling Heights, Michigan 48314, United States
  • Research Site
    Sterling Heights, Michigan, United States
  • Research Site
    Billings, Montana 59101, United States
  • Research Site
    Billings, Montana, United States
  • Research Site
    Flemington, New Jersey 08822, United States
  • Research Site
    Flemington, New Jersey, United States
  • Research Site
    Johnson City, New York 13790, United States
  • Research Site
    Johnson City, New York, United States
  • Research Site
    Oklahoma City, Oklahoma 73104, United States
  • Research Site
    Oklahoma City, Oklahoma, United States
  • Research Site
    Drexel Hill, Pennsylvania 19026, United States
  • Research Site
    Drexel Hill, Pennsylvania, United States
  • Research Site
    Dunmore, Pennsylvania 18512, United States
  • Research Site
    Dunmore, Pennsylvania, United States
  • Research Site
    Radnor, Pennsylvania 19087, United States
  • Research Site
    Radnor, Pennsylvania, United States
  • Research Site
    Columbia, South Carolina 29203, United States
  • Research Site
    Columbia, South Carolina, United States
  • Research Site
    Germantown, Tennessee 38138, United States
  • Research Site
    Germantown, Tennessee, United States
  • Research Site
    Austin, Texas 78705, United States
  • Research Site
    Austin, Texas, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Houston, Texas 77074, United States
  • Research Site
    Houston, Texas, United States
  • Research Site
    Graz, 8036, Austria
  • Research Site
    Graz, Austria
  • Research Site
    Innsbruck, 6020, Austria
  • Research Site
    Innsbruck, Austria
  • Research Site
    Klagenfurt, 9026, Austria
  • Research Site
    Klagenfurt, Austria
  • Research Site
    Linz, 4010, Austria
  • Research Site
    Linz, Austria
  • Research Site
    Rankweil, 6830, Austria
  • Research Site
    Rankweil, Austria
  • Research Site
    Wien, 1090, Austria
  • Research Site
    Wien, Austria
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Toronto, Ontario, Canada
  • Research Site
    Sainte-Foy, Quebec G1V 4G5, Canada
  • Research Site
    Sainte-Foy, Quebec, Canada
  • Research Site
    Bad Berka, 99437, Germany
  • Research Site
    Bad Berka, Germany
  • Research Site
    Dresden, 01307, Germany
  • Research Site
    Dresden, Germany
  • Research Site
    Halle/ Saale, 06120, Germany
  • Research Site
    Halle/ Saale, Germany
  • Research Site
    Hemer, 58675, Germany
  • Research Site
    Hemer, Germany
  • Research Site
    Budapest, 1125, Hungary
  • Research Site
    Budapest, 1529, Hungary
  • Research Site
    Budapest, Hungary
  • Research Site
    Edeleny, 3780, Hungary
  • Research Site
    Edeleny, Hungary
  • Research Site
    Gyula, 5703, Hungary
  • Research Site
    Gyula, Hungary
  • Research Site
    Matrahaza, 3233, Hungary
  • Research Site
    Matrahaza, Hungary
  • Research Site
    Pecs, 7623, Hungary
  • Research Site
    Pecs, Hungary
  • Research Site
    Szekesfehervar, 8000, Hungary
  • Research Site
    Szekesfehervar, Hungary
  • Research Site
    Torokbalint, 2045, Hungary
  • Research Site
    Torokbalint, Hungary
  • Research Site
    Zalaegerszeg - Pozva, 8900, Hungary
  • Research Site
    Zalaegerszeg - Pozva, Hungary
  • Research Site
    Cork, Cork, Ireland
  • Research Site
    Cork, Ireland
  • Research Site
    Dublin, 4, Ireland
  • Research Site
    Dublin, 8, Ireland
  • Research Site
    Dublin, Ireland
  • Research Site
    Novara, 28100, Italy
  • Research Site
    Novara, Italy
  • Research Site
    Orbassano, 10043, Italy

Showing the first 100 of 113 sites across 8 countries. Choose a country and city above to see the rest.

10

References and documents

11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006, a primary completion of Dec 2008 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2010, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2006
First posted
Dec 19, 2006
Start
Dec 2006
Primary completionActual
Dec 2008
CompletionActual
Feb 2009
Results first posted
Oct 21, 2010
Last update
Oct 24, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00413283
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Dec 19, 2006
Start date
Dec 2006
Primary completion
Dec 2008
Completion
Feb 2009
Results posted
Oct 21, 2010
Last update
Oct 24, 2013

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romiplostim

Start the discussion